JP2020501598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501598A5 JP2020501598A5 JP2019536459A JP2019536459A JP2020501598A5 JP 2020501598 A5 JP2020501598 A5 JP 2020501598A5 JP 2019536459 A JP2019536459 A JP 2019536459A JP 2019536459 A JP2019536459 A JP 2019536459A JP 2020501598 A5 JP2020501598 A5 JP 2020501598A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 52
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395832P | 2016-09-16 | 2016-09-16 | |
| US62/395,832 | 2016-09-16 | ||
| US201762519590P | 2017-06-14 | 2017-06-14 | |
| US62/519,590 | 2017-06-14 | ||
| PCT/US2017/050851 WO2018052818A1 (en) | 2016-09-16 | 2017-09-09 | Anti-pd-1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501598A JP2020501598A (ja) | 2020-01-23 |
| JP2020501598A5 true JP2020501598A5 (enExample) | 2020-10-22 |
| JP7072576B2 JP7072576B2 (ja) | 2022-05-20 |
Family
ID=61620151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536459A Active JP7072576B2 (ja) | 2016-09-16 | 2017-09-09 | 抗ｐｄ－１抗体 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11028173B2 (enExample) |
| EP (3) | EP3512885B1 (enExample) |
| JP (1) | JP7072576B2 (enExample) |
| KR (1) | KR102391338B1 (enExample) |
| CN (1) | CN109923126B (enExample) |
| AU (1) | AU2017327828B2 (enExample) |
| BR (1) | BR112019005129A2 (enExample) |
| CA (1) | CA3037144A1 (enExample) |
| DK (1) | DK4339615T3 (enExample) |
| ES (2) | ES2977137T3 (enExample) |
| FI (2) | FI4339615T3 (enExample) |
| FR (1) | FR25C1022I2 (enExample) |
| HR (1) | HRP20251501T1 (enExample) |
| HU (2) | HUE067813T2 (enExample) |
| LT (2) | LT4339615T (enExample) |
| MY (1) | MY199683A (enExample) |
| NL (1) | NL301362I2 (enExample) |
| NO (1) | NO2026007I1 (enExample) |
| PH (1) | PH12019500571A1 (enExample) |
| PL (1) | PL4339615T3 (enExample) |
| PT (1) | PT4339615T (enExample) |
| RS (1) | RS67443B1 (enExample) |
| RU (1) | RU2752832C2 (enExample) |
| SI (1) | SI4339615T1 (enExample) |
| SM (1) | SMT202500445T1 (enExample) |
| TW (1) | TWI772326B (enExample) |
| WO (1) | WO2018052818A1 (enExample) |
| ZA (1) | ZA201901865B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7469305B2 (ja) * | 2018-11-19 | 2024-04-16 | バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド | 抗ｐｄ－１抗体およびその使用 |
| CN112203642B (zh) | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| TWI869398B (zh) * | 2019-05-10 | 2025-01-11 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| US12404333B2 (en) | 2019-08-29 | 2025-09-02 | Remegen Co., Ltd. | Anti PD-L1 antibody and use thereof |
| CN110787292B (zh) * | 2020-01-06 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 一种细胞程序性死亡受体1抗体制剂及其用途 |
| WO2021139780A1 (en) * | 2020-01-10 | 2021-07-15 | Shanghai Henlius Biotech, Inc. | Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same |
| JP7692918B6 (ja) * | 2020-01-21 | 2025-07-17 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ｌａｇ３モノクローナル抗体、その製造方法および使用 |
| CN113336847B (zh) * | 2021-02-03 | 2022-08-23 | 上海莱馥医疗科技有限公司 | 一种抗pd-1抗体 |
| EP4293046A4 (en) * | 2021-02-10 | 2025-03-05 | Shanghai Jemincare Pharmaceuticals Co., Ltd. | Anti-pd-1 antibody and use thereof |
| WO2024025986A1 (en) * | 2022-07-28 | 2024-02-01 | Merck Sharp & Dohme Llc | Pharmaceutical compositions of programmed death receptor 1 (pd-1) antibodies and ph20 variants or fragments thereof |
| CN119894932A (zh) * | 2022-07-28 | 2025-04-25 | 默沙东有限责任公司 | 程序性死亡受体1（PD-1）抗体和rHuPH20或其变体或片段的药物组合物 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
| WO2026067794A1 (en) * | 2024-09-30 | 2026-04-02 | Shen Shi Pharmaceuticals (Shanghai) Co., Ltd. | Trispecific antibodies and uses thereof |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| WO1985003357A1 (en) | 1984-01-30 | 1985-08-01 | Icrf Patents Ltd. | Improvements relating to growth factors |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| EP0353450B1 (en) | 1988-06-24 | 1995-03-29 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| CN1033030C (zh) | 1988-06-24 | 1996-10-16 | 唐化学原料公司 | 大环双官能螯合剂及其配合物和抗体共轭物的制备方法 |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| EP0494135B1 (en) | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| AU2937597A (en) * | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20110250203A1 (en) * | 2008-08-29 | 2011-10-13 | Symphogen A/S | Anti-cd5 antibodies |
| EP2755688A4 (en) * | 2011-10-27 | 2014-08-06 | Nkt Therapeutics Inc | HUMANIZED ANTIBODIES AGAINST INKT |
| US20150086570A1 (en) * | 2012-03-29 | 2015-03-26 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
| EP3218409A2 (en) | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| SI3356404T1 (sl) * | 2015-10-02 | 2021-11-30 | F. Hoffmann-La Roche Ag | Protitelesa proti PD1 in postopki uporabe |
-
2017
- 2017-09-09 SI SI201731637T patent/SI4339615T1/sl unknown
- 2017-09-09 BR BR112019005129-5A patent/BR112019005129A2/pt active Search and Examination
- 2017-09-09 FI FIEP24150762.3T patent/FI4339615T3/sv active
- 2017-09-09 ES ES17851358T patent/ES2977137T3/es active Active
- 2017-09-09 PL PL24150762.3T patent/PL4339615T3/pl unknown
- 2017-09-09 AU AU2017327828A patent/AU2017327828B2/en active Active
- 2017-09-09 HU HUE17851358A patent/HUE067813T2/hu unknown
- 2017-09-09 SM SM20250445T patent/SMT202500445T1/it unknown
- 2017-09-09 CA CA3037144A patent/CA3037144A1/en active Pending
- 2017-09-09 EP EP17851358.6A patent/EP3512885B1/en active Active
- 2017-09-09 WO PCT/US2017/050851 patent/WO2018052818A1/en not_active Ceased
- 2017-09-09 RU RU2019107134A patent/RU2752832C2/ru active
- 2017-09-09 MY MYPI2019001409A patent/MY199683A/en unknown
- 2017-09-09 HR HRP20251501TT patent/HRP20251501T1/hr unknown
- 2017-09-09 LT LTEP24150762.3T patent/LT4339615T/lt unknown
- 2017-09-09 DK DK24150762.3T patent/DK4339615T3/da active
- 2017-09-09 CN CN201780056868.5A patent/CN109923126B/zh active Active
- 2017-09-09 EP EP25204711.3A patent/EP4696785A3/en active Pending
- 2017-09-09 ES ES24150762T patent/ES3055536T3/es active Active
- 2017-09-09 EP EP24150762.3A patent/EP4339615B1/en active Active
- 2017-09-09 JP JP2019536459A patent/JP7072576B2/ja active Active
- 2017-09-09 KR KR1020197010711A patent/KR102391338B1/ko active Active
- 2017-09-09 RS RS20251199A patent/RS67443B1/sr unknown
- 2017-09-09 PT PT241507623T patent/PT4339615T/pt unknown
- 2017-09-15 TW TW106131824A patent/TWI772326B/zh active
-
2019
- 2019-03-13 US US16/352,194 patent/US11028173B2/en active Active
- 2019-03-15 PH PH12019500571A patent/PH12019500571A1/en unknown
- 2019-03-26 ZA ZA2019/01865A patent/ZA201901865B/en unknown
-
2021
- 2021-04-29 US US17/244,025 patent/US11685783B2/en active Active
-
2025
- 2025-06-02 HU HUS2500024C patent/HUS2500024I1/hu unknown
- 2025-06-03 FR FR25C1022C patent/FR25C1022I2/fr active Active
-
2026
- 2026-01-19 NL NL301362C patent/NL301362I2/nl unknown
- 2026-01-19 FI FIC20260002C patent/FIC20260002I1/fi unknown
- 2026-01-21 LT LTPA2026505C patent/LTPA2026505I1/lt unknown
- 2026-01-22 NO NO2026007C patent/NO2026007I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2019107134A (ru) | Анти-pd-1 антитела | |
| JP2022542165A5 (enExample) | ||
| RU2019116661A (ru) | Антитела против pd-l1 и их варианты | |
| JP2017521054A5 (enExample) | ||
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| JP2017535257A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2019536740A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP2018528759A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2018512170A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2022514734A5 (enExample) | ||
| JP2014524902A5 (enExample) | ||
| JP2024538148A5 (enExample) |